IL17A and myasthenia gravis: By demonstrating significant reductions in Th17 cell frequency, IL-17 levels, and clinical severity scores, our findings underscore the pivotal role of the Th17/IL-17 axis in MG immunopathology (21, 29) and highlight secukinumab as a promising targeted therapy.